How to buy InMed Pharmaceuticals stock (InMed Pharmaceuticals)

InMed Pharmaceuticals is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.35 – a decrease of 15.53% over the previous week. InMed Pharmaceuticals employs 13 staff and has a trailing 12-month revenue of around $4.6 million.

Our top picks for where to buy InMed Pharmaceuticals stock

Buy InMed Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

InMed Pharmaceuticals stock price (NASDAQ: INM)

Use our graph to track the performance of INM stocks over time.

InMed Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$4.35
52-week range	$2.42 - $9.44
50-day moving average more info button	$4.93
200-day moving average more info button	$5.42
Wall St. target price	$20.00
PE ratio more info button	0.0189
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$230.40

Is it a good time to buy InMed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InMed Pharmaceuticals price performance over time

Historical closes compared with the close of $5.19 from 2024-12-17

1 week (2024-12-12)	0.78%
1 month (2024-11-19)	19.31%
3 months (2024-09-19)	1,801.10%
6 months (2024-06-18)	1,780.43%

1 year (2023-12-19)	1,404.35%
2 years (2022-12-19)	-84.08%
3 years (2021-12-17)	727.5
5 years (2019-12-19)	2953.5

Is InMed Pharmaceuticals stock undervalued or overvalued?

Valuing InMed Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of InMed Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

InMed Pharmaceuticals's P/E ratio

InMed Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, InMed Pharmaceuticals shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, InMed Pharmaceuticals's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Aphria (APHA.US): 0.00
• Moderna (MRNA.US): 0.00
• Regeneron Pharmaceuticals (REGN.US): 17.67
• AbbVie (ABBV.US): 60.29

InMed Pharmaceuticals financials

Revenue TTM	$4.6 million
Gross profit TTM	$1.4 million
Return on assets TTM	-39.22%
Return on equity TTM	-72.09%
Profit margin	-166.94%
Book value	$1.03
Market Capitalization more info button	$3.1 million

TTM: trailing 12 months

InMed Pharmaceuticals share dividends

We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• AbbVie (ABBV.US) (3.79% forward annual dividend yield)

Have InMed Pharmaceuticals's shares ever split?

InMed Pharmaceuticals's shares were split on a 1:20 basis on 13 November 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.

InMed Pharmaceuticals share price volatility

Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $2.42 up to $9.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 0.711. This would suggest that InMed Pharmaceuticals's shares are less volatile than average (for this exchange).

To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Aphria (APHA.US): 2.6198
• Moderna (MRNA.US): 1.69
• Regeneron Pharmaceuticals (REGN.US): 0.142
• AbbVie (ABBV.US): 0.613

InMed Pharmaceuticals overview

InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.

Frequently asked questions

null
What percentage of InMed Pharmaceuticals is owned by insiders or institutions?
Currently 0.616% of InMed Pharmaceuticals shares are held by insiders and 9.503% by institutions. How many people work for InMed Pharmaceuticals?
Latest data suggests 13 work at InMed Pharmaceuticals. When does the fiscal year end for InMed Pharmaceuticals?
InMed Pharmaceuticals's fiscal year ends in June. Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals's address is: 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 What is InMed Pharmaceuticals's ISIN number?
InMed Pharmaceuticals's international securities identification number is: CA4576375022